Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory

Arnold, Melina; Karim‐Kos, Henrike E.; Coebergh, Jan Willem; Byrnes, Graham; Antilla, Ahti; Ferlay, Jacques; Renehan, Andrew G; Forman, David; Soerjomataram, Isabelle

doi:10.1016/j.ejca.2013.09.002

Cited by 436 publications

(303 citation statements)

References 57 publications

Supporting

Mentioning

274

Contrasting

Unclassified

Order By: Relevance

“…While the incidence of autopsy-detected cancers is roughly the same in different parts of the world, the incidence of clinically diagnosed PCa varies widely, being highest in Northern and Western Europe (> 200 per 100,000 men) [3]. Besides the increased opportunistic screening with PSA, this is suggested to be a consequence of exogenous factors, such as diet, chronic inflammation, sexual behaviour, and exposure to ultraviolet radiation [4].…”

Section: Introductionmentioning

confidence: 99%

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

et al. 2017

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

et al. 2017

View full text Add to dashboard Cite

“…FS prevalence evaluated by individual symptoms Figure 1 summarises the prevalence of individual Flammer syndrome symptoms (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15) in two groups of comparison-the BPostmenopausal breast cancer^patients versus the reference group of BBC-free^individuals. Higher prevalence in postmenopausal breast cancer (red) has been demonstrated for altogether 11 symptoms.…”

Section: General Statisticsmentioning

confidence: 99%

“…Moreover, in the Eastern and Central European countries, amongst the four most common cancers, specifically the postmenopausal breast cancer started to approach the incidence levels earlier registered for the Northern and Western Europe, where their rates traditionally were the highest ones within the European area [2]. Increasing trends in the postmenopausal breast cancer prevalence, even for the European countries earlier demonstrating relatively stable incidence rates of the disease, are highly alarming for the healthcare givers.…”

Section: Introduction Postmenopausal Breast Cancer As the European Chmentioning

confidence: 99%

Postmenopausal breast cancer: European challenge and innovative concepts

et al. 2017

View full text Add to dashboard Cite

Breast cancer (BC) epidemic is recognised now worldwide as the reality of the early twenty-first century. Increasing trends in the postmenopausal BC prevalence, even for the European countries earlier demonstrating relatively stable incidence rates of the disease, are highly alarming for the healthcare givers. This new actuality requires a substantial revision of the paradigm currently applied to the BC management and creation of highly innovative concepts. Current multi-centred study highlights new complex mechanisms of the development and progression of the postmenopausal BC. Innovative concepts are presented which argue for more effective predictive and preventive approaches well justified in view of the clusters of the symptoms analysed here and demonstrated as highly prevalent in the postmenopausal breast cancer versus BC-free individuals. Another conceptual novelty presented here is a new interpretation of the BSeed and Soilt heory of metastasis in BC. According to the new concept, the Bpre-metastatic niches^(BSoil^) are created by a systemic hypoxia a long time before the breast malignancy is clinically manifested.

show abstract

“…Он представляет собой се-рьезную проблему для здравоохранения, особенно в развитых странах, в которых выше пропорция пожилых мужчин в общей популяции. Наиболее высокая распространенность наблюдается в странах Северной и Западной Европы (более 200 случаев на The current abilities of third-generation luteinizing hormone-releasing hormone antagonists in the treatment of hormone-responsive prostate cancer 100 000 населения), а в странах Восточной и Южной Европы от-мечается постоянный рост показателей [3]. Сохраняется различие в выживаемости у мужчин в странах Восточной Европы и осталь-ных странах Европы.…”

unclassified

The current abilities of third-generation luteinizing hormone-releasing hormone antagonists in the treatment of hormone-responsive prostate cancer

Грицкевич¹,

Медведев²,

Теплов³

et al. 2014

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

4 prof. S.v. ochapovsky territorial Clinical hospital one, Krasnodar; 5 p.A. herzen Moscow oncology research institute, Ministry of health of russia, Moscow в обзоре представлены возможности антагонистов лютеинизирующего гормона -рилизинг-гормона (ЛГрГ) третьего по-коления в лечении гормоночувствительного рака предстательной железы (рпЖ). в настоящее время наиболее изученным и применяемым антагонистом ЛГрГ является дегареликс. Он приводит к быстрому подавлению тестостерона и снижению простатспецифического антигена без колебания уровня тестостерона, и, таким образом, предотвращает риск клиниче-ской вспышки при распространенном заболевании. последние исследования показали, что терапия дегареликсом улуч-шает результаты лечения рпЖ по сравнению с агонистами ЛГрГ с точки зрения безрецидивной выживаемости. пред-полагается, что дегареликс задерживает прогрессирование кастрационно-резистентного рака предстательной железы и имеет более существенное влияние на метастазы в костях, щелочную фосфатазу и фолликулостимулирующий гормон. в последнее время получены результаты клинических исследований, подтверждающие целесообразность назначения дега-реликса во второй линии гормонотерапии при биохимическом прогрессировании болезни на фоне курсового применения агонистов ЛГрГ. Дегареликс обладает хорошей переносимостью, низкой токсичностью и отсутствием системных аллер-гических реакций. таким образом, последняя генерация антагонистов ЛГрГ вносит новый и важный вклад в стратегию антиандрогенной терапии гормоночувствительного рпЖ. Ключевые слова: андрогенная депривация, дегареликс, антагонисты лютеинизирующего гормона рилизинг-гормона, рак предстательной железы, гормоночувствительный рак предстательной железы.the review shows the abilities of third-generation luteinizing hormone-releasing hormone (lhrh) antagonists in the treatment of hormone-responsive prostate cancer (pC). Degarelix is presently the most studied and most commonly used lhrh antagonist. it leads to a rapid suppression of testosterone and a reduction in prostate-specific antigen without ranging the level of testosterone and thus prevents the risk of a clinical exacerbation of the disseminated disease. the latest investigations have shown that therapy with degarelix versus lhrh agonists improves the results of pC treatment in relapse-free survival rates. Degarelix is assumed to delay the progression of castration-resistant prostate cancer and to have a more considerable effect on bone metastases, alkaline phosphatase (Ap) and follicle-stimulating hormone. the results of clinical trials, which support that it is expedient to use degarelix in second-line hormone therapy or the biochemical progression of the disease during the cycle therapy with lhrh agonists, have been recently obtained. Degarelix shows good tolerability, low toxicity, and no systemic allergic reactions. thus, the newest-generation lhrh antagonists make novel and important contributions to the anti-androgenic therapy strategy for hormone-responsive pC.

show abstract

Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory

Cited by 436 publications

References 57 publications

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Postmenopausal breast cancer: European challenge and innovative concepts

The current abilities of third-generation luteinizing hormone-releasing hormone antagonists in the treatment of hormone-responsive prostate cancer

Contact Info

Product

Resources

About